Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

Danish biotech giant Novo Nordisk is trading at an extremely attractive valuation — particularly relative to its main rival, ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales ...

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...

VIG's recent rebalancing impacts its holdings, yield, and dividend growth streak. Read here for a comparison with SPY, DGRO, ...

Eli Lilly LLY has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...